Association of High Pulse Pressure With Proteinuria in Subjects With Diabetes, Prediabetes, or Normal Glucose Tolerance in a Large Japanese General Population Sample

Yuichiro Yano, MD
Yuji Sato, MD, PhD
Shoichi Fujimoto, MD, PhD
Tsuneo Konta, MD, PhD
Kunitoshi Iseki, MD, PhD
Toshiki Moriyama, MD, PhD
Kunihiro Yamagata, MD, PhD
Kazuhiko Tsuruya, MD, PhD
Hideaki Yoshida, MD, PhD
Koichi Asahi, MD, PhD
Issei Kurahashi, MD, PhD
Yasuo Ohashi, MD, PhD
Tsuyoshi Watanabe, MD, PhD

OBJECTIVE—To examine whether there is a difference in the association between high pulse pressure and proteinuria, independent of other blood pressure (BP) indices, such as systolic or diastolic BP, among subjects with diabetes, prediabetes, or normal glucose tolerance.

RESULTS—The prevalence of proteinuria was different among subjects with diabetes, prediabetes, and normal glucose tolerance (11.3 vs. 5.0 vs. 3.9%, respectively; \( P < 0.001 \)). In subjects with diabetes, but not those with prediabetes or normal glucose tolerance, high pulse pressure was associated with proteinuria independently of significant covariates, including systolic BP (odds ratio 1.15 [95% CI 1.04–1.28]) or diastolic or mean BP (all \( P < 0.01 \)). In patients with diabetes, a +1 SD increase of pulse pressure (+13 mmHg) was associated with proteinuria, even after adjustment for systolic BP (1.07 [1.00–1.13]) or diastolic or mean BP (all \( P < 0.05 \)).

CONCLUSIONS—Among the Japanese general population, there was a significant difference in the association between high pulse pressure and proteinuria among subjects with diabetes, prediabetes, and normal glucose tolerance. Only in diabetes was high pulse pressure associated with proteinuria independent of systolic, diastolic, or mean BP levels.

Diabetes Care 35:1310–1315, 2012
database of subjects recruited from the national health checkup system in Japan.

RESEARCH DESIGN AND METHODS

Study population
This study was performed as a part of the prospective ongoing "Research on the Positioning of Chronic Kidney Disease in Specific Health Check and Guidance in Japan" project. A new annual health check program, "The Specific Health Check and Guidance in Japan", was started by the Japanese government in 2008, targeting early diagnosis and intervention for metabolic syndrome. The target population comprises Japanese citizens between the ages of 40 and 74 years. In Japan, there are 47 administrative divisions (prefectures), and 13 of these prefectures (Yamagata, Miyagi, Fukushima, and Niigata from the Tohoku region in northeastern Japan; Tokyo, Kanagawa, and Ibaraki from the Kanto region in central Japan; Osaka, Okayama, and Kochi from the Kansai, Tyugoku, or Shikoku region in western Japan; and Fukuoka, Miyazaki, and Okinawa from the Kyushu region in southern Japan), which were randomly distributed across Japan, agreed with the aims of this study and performed data collection prospectively from 2008 to 2009. Data were sent to an independent data center, the nonprofit organization Japan Clinical Research Support Unit after anonymization in a linkable fashion, and verified by trained staff (K.I. and Y.O.). After that, the database was locked with a security password, which contained the participant's information managed by a research ID number but did not contain the participant's name, and was sent to each investigator on a recordable compact disc.

There were a total of 346,942 subjects (mean age, 63.4 years; 41% [n = 141,938] men) for whom information on age, sex, BP, BMI, habitual smoking or drinking, use of antihypertensive drugs, and previous history of cardiovascular diseases (i.e., stroke and cardiac diseases such as angina and myocardial infarction) were available, as well as data on the serum creatinine level and dipstick urine test for proteinuria (19). Some of the regions participating in our project (i.e., Okinawa and Osaka) concomitantly performed regular health checkups for employees as legally mandated in Japan; as a result, the database used in the present analysis also included subjects aged 20–39 years (n = 2,025). Among the 346,942 subjects, 29,820 subjects with a previous history of cardiovascular disease, 243 subjects with chronic kidney disease stage 5 (estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m²), and 47 subjects with both were excluded from the present analysis. Moreover, 88,101 subjects with insufficient blood sampling data of glucose and lipid parameters were excluded. Supplementary Table 1 shows the differences in clinical characteristics between subjects who were included in the present analysis (n = 228,778) and those who had missing data (n = 88,101).

The study was conducted according to the guidelines of the Declaration of Helsinki and Ethical Guidelines for Epidemiological Research (1 November 2007, Ministry of Education, Culture, Sports, Science, and Technology and Ministry of Health, Labor, and Welfare of Japan). Ethical approval from the respective institutional review boards was also granted.

Baseline measurement
All subjects completed a self-administered questionnaire to document their medical history, current medications, smoking habits (current smoker or not), and alcohol intake (daily drinker or not). The study physicians performed a physical examination of each subject and rechecked their medical history to improve the precision of the information. Body height and weight were measured in light clothing without shoes, and the BMI was calculated (kg/m²). BP measurement and blood and urine sampling were performed at each local medical institution to cooperate with the nationwide medical checkup. According to the recommendations of the Japanese Ministry of Health, Labor, and Welfare (http://www.mhlw.go.jp/bunya/shakahoshou/iyousuido01/info03a.html), BP was measured by medical staff using a standard sphygmomanometer or an automated device on the right arm after the subject had rested for 5 min in a seated position with the legs not crossed. Conversation as well as alcohol/caffeine consumption was also avoided before measurement. Pulse pressure was calculated as systolic BP – diastolic BP, and mean BP was calculated as diastolic BP + (pulse pressure/3).

Blood samples were collected after an overnight fast and were assayed within 24 h with an automatic clinical chemical analyzer. All measurements were conducted locally rather than at a central laboratory without calibration among different laboratories, despite the fact that beginning several years ago, standardized methods to measure laboratory data were recommended and widely adopted by the activity of the Japan Society of Clinical Chemistry. The value for hemoglobin A1c (HbA1c) was estimated as a National Glycohemoglobin Standardization Program equivalent value calculated with the following equation (20): HbA1c (%) = HbA1c (Japan Diabetes Society) (%) + 0.4%.

Diabetes was defined in accordance with American Diabetes Association guidelines (17) as a fasting glucose concentration of 126 mg/dL or higher, HbA1c 6.5% or higher, or self-reported use of antihyperglycemic drugs. Diagnosis of prediabetes was based on the new American Diabetes Association criterion of impaired fasting glucose (fasting plasma glucose 100–125 mg/dL) or HbA1c 5.7–6.4%, or both (17).

Urine analysis by the dipstick method was performed on a single spot urine specimen collected in the early morning after overnight fasting. Urine dipstick results are interpreted by the medical staff in each local medical institution and recorded as −, ±, 1+, 2+, and 3+. In Japan, it is recommended and widely adopted by the activity of the Japanese Committee for Clinical Laboratory Standards (http://jccls.org/) that all urine dipstick tests be manufactured so that a urine dipstick result of 1+ will correspond to a urinary protein level of 30 mg/dL. In the current study, proteinuria was defined as 1+ or more. eGFR was derived using the following equation (21): eGFR (mL/min/1.73 m²) = 194 × age (years)−0.287 × serum creatinine (mg/dL)−1.094 × (if women × 0.739).

Statistical analysis
All statistical analyses were performed with SPSS version 18.0j software (SPSS, Chicago, IL). Data were expressed as the means ± SD (age, BMI, eGFR, and BP values) or median and interquartile range (glucose and lipid parameters). Clinical parameters and BP or metabolic values according to the presence of diabetes or prediabetes were compared using ANOVA, and categorical parameters were compared with the χ² test. We subdivided the study population according to the quintiles of pulse pressure, and the prevalence of proteinuria (≥1+) was compared by χ² test among each group of the quintiles of pulse pressure separately in subjects with diabetes, prediabetes, or normal glucose tolerance, respectively. The highest quintile of pulse pressure (≥63 mmHg, n = 40,511) was defined as the high pulse pressure group in the present analysis.

Next, we used a multivariable logistic regression analysis to examine the independent...
association of high pulse pressure with proteinuria (≥1+), separately in subjects with diabetes, prediabetes, or normal glucose tolerance, respectively. In the initial model (Model 1), these associations were assessed with adjustment for age, sex, BMI, current smoking and daily drinking, the presence of antihypertensive medications, and eGFR. Extended models were used to assess whether the association of high pulse pressure with proteinuria (≥1+) was attenuated by the potential confounding effects of glucose and lipid parameters (Model 2) and systolic BP (Model 3). In addition, to minimize the influence of systolic BP in the association between pulse pressure and proteinuria, we examined the association only in patients with diabetes whose systolic BP was within the normal BP range (i.e., <130 mmHg) (22). Finally, we examined the association of a 1 SD increase of pulse pressure (+13 mmHg), rather than pulse pressure as a dichotomous variable, with proteinuria in patients with diabetes by a multivariable logistic regression analysis. Statistical significance was defined as P < 0.05.

RESULTS

Clinical characteristics of the study population
The mean age ± SD of the 228,778 subjects was 63.2 ± 8.9 years, and 89,877 of the subjects (39.3%) were men. There were 27,913 subjects (12.2% of the total subject population) with diabetes, of whom 10,980 subjects (39.1%) were taking antihyperglycemic medications. There were 100,214 subjects (43.8%) with prediabetes. The clinical characteristics according to the presence of diabetes or prediabetes are shown in Table 1. Compared with subjects with normal glucose tolerance (as a reference), the odds ratio (OR) for the increased risk of proteinuria (≥1+) in diabetes itself was 2.14 (95% CI 2.03–2.25), and that in prediabetes was 1.10 (1.05–1.14), even after adjustment for significant covariates, such as age, sex, BMI, current smoking and daily drinking, the presence of antihypertensive medications, and systolic BP level (both P < 0.001).

Pulse pressure and proteinuria
Clinical characteristics and metabolic or BP parameters according to the quintile of pulse pressure are shown in Supplementary Table 2. The increasing prevalence of proteinuria (≥1+) in accordance with the increasing pulse pressure was more prominent in subjects with diabetes than those without diabetes (Fig. 1). Supplementary Table 3 shows the prevalence of proteinuria subdivided by the dipstick positive scale according to the quintile of pulse pressure with or without diabetes.

Next, a multivariable logistic regression analysis was performed to examine the independent association between the highest quintile of pulse pressure and proteinuria, separately in subjects with diabetes, prediabetes, and normal glucose tolerance. In patients with diabetes, the highest quintile of pulse pressure (≥63 mmHg) was positively associated with proteinuria, independently of significant covariates, including systolic BP (Models 1–3 in Table 2). When we examined the association between pulse pressure and proteinuria only in patients with diabetes whose systolic BP was within the normal range (i.e., <130 mmHg, n = 11,074 [39.7%]), the highest quintile of pulse pressure still remained significantly associated with proteinuria (OR 1.46 [95% CI 1.03–2.08]; P = 0.04, respectively), even after adjustment for significant covariates, as shown in Model 2 in Table 2. When diastolic BP or mean BP was entered into Model 3 in Table 2, the association between the highest quintile of pulse pressure and proteinuria still remained significant (1.61 [1.49–1.75] and 1.42 [1.31–1.55]; both P < 0.001, respectively). In contrast, the highest quintile of pulse pressure in subjects with prediabetes or normal glucose tolerance was not associated with proteinuria independently of systolic BP (Model 3 in Table 2). When

| Table 1—Characteristics of the study population according to the presence of diabetes or prediabetes |
| Age (years) | Diabetes (n = 27,913) | Prediabetes (n = 100,214) | Normal glucose tolerance (n = 100,651) | P value |
|------------|----------------------|--------------------------|----------------------------------|--------|
| Diabetes (%) | 65.2 ± 7.3 | 64.2 ± 7.9 | 61.6 ± 9.8 | <0.001 |
| Prediabetes (%) | 65.1 ± 7.3 | 64.2 ± 7.9 | 61.6 ± 9.8 | <0.001 |
| Normal glucose tolerance (%) | 65.2 ± 7.3 | 64.2 ± 7.9 | 61.6 ± 9.8 | <0.001 |
| Sex, n (%) | 14,626 (52.4%) | 40,077 (40.0%) | 35,174 (34.9%) | <0.001 |
| BMI (kg/m²) | 24.1 ± 3.7 | 23.3 ± 3.3 | 22.5 ± 3.1 | <0.001 |
| Current smoker (%) | 4,846 (17.4%) | 12,960 (12.9%) | 13,971 (13.9%) | <0.001 |
| Daily drinker (%) | 7,162 (25.7%) | 22,825 (22.8%) | 21,521 (21.4%) | <0.001 |
| eGFR (ml/min/1.73 m²) | 76.2 ± 17.8 | 74.7 ± 15.6 | 76.1 ± 15.9 | <0.001 |
| Proteinuria ≥1+, n (%) | 3,164 (11.3%) | 5,013 (5.0%) | 3,913 (3.9%) | <0.001 |
| Glucose and lipid parameters | | | | |
| Fasting glucose (mg/dL)* | 125.0 (100.0–143.0) | 98.0 (90.0–105.0) | 89.0 (84.0–93.0) | <0.001 |
| HbA1c % | 6.2 (5.6–6.9) | 5.4 (5.3–5.6) | 5.0 (4.8–5.1) | <0.001 |
| Triglycerides (mg/dL)* | 112.0 (79.0–162.0) | 101.0 (74.0–142.0) | 91.0 (67.0–127.0) | <0.001 |
| LDL (mg/dL)* | 123.0 (104.0–145.0) | 127.0 (108.0–148.0) | 124.0 (105.0–144.0) | <0.001 |
| HDL (mg/dL)* | 57.0 (48.0–86.0) | 60.0 (51.0–72.0) | 63.0 (53.0–75.0) | <0.001 |
| Antihypertensive drugs, n (%) | 11,101 (39.8) | 29,157 (29.1) | 21,419 (21.3) | <0.001 |
| Antihyperlipidemic drugs, n (%) | 6,823 (24.4) | 17,440 (17.4) | 12,233 (12.2) | <0.001 |
| Antihyperglycemic drugs, n (%) | 10,980 (39.1) | 0 (0) | 0 (0) | <0.001 |

BP parameters

| Systolic BP (mmHg) | 133.4 ± 17.5 | 129.7 ± 17.0 | 125.7 ± 17.2 | <0.001 |
| Diastolic BP (mmHg) | 77.1 ± 10.8 | 76.8 ± 10.5 | 75.1 ± 10.7 | <0.001 |
| Pulse pressure (mmHg) | 56.2 ± 13.4 | 52.9 ± 12.4 | 50.6 ± 12.2 | <0.001 |

Data are expressed as the means ± SD or percentage. P values were obtained by ANOVA or χ² test. *Variables with skewed distribution are expressed as median (interquartile range).
we examined the risk of the highest quintile of pulse pressure on proteinuria among subjects without antihypertensive medications \((n = 167,110)\), the conclusion remained unchanged (Model 4 in Table 2). Use of antihyperglycemic or anti-hyperlipidemic drugs did not influence any of the above results (data not shown). In contrast, systolic BP, used as an adjusted factor in Model 3 in Table 2, showed significant associations with proteinuria in subjects with diabetes, prediabetes, and normal glucose tolerance (data not shown).

Finally, we analyzed the association of a +1 SD increase of pulse pressure (+13 mmHg), rather than pulse pressure as a dichotomous variable, with proteinuria in patients with diabetes. We found that a +1 SD increase of pulse pressure was associated with proteinuria independently of significant covariates, including systolic BP (Table 3), diastolic BP, or mean BP (data not shown).

**CONCLUSIONS**—In this nationwide study of 228,778 Japanese people (mean age 63.2 years) who had no known cardiovascular disease, we demonstrated for the first time that there was a significant difference in the association between the highest quintile of pulse pressure (\(\geq 63\) mmHg) and proteinuria (\(\geq 1+\) on dipstick) among subjects with diabetes, prediabetes, and normal glucose tolerance. The cross-sectional design of the current study did not allow us to elucidate the pathophysiological pathway linking high pulse pressure and proteinuria (\(\geq 1+\)). However, there are some possible explanations for the observed association.

**Pulse pressure, proteinuria, and patients with diabetes**

Since the glomerular afferent arteriolo provides relatively low resistance, the glomerulus is susceptible to barotrauma if the pulse pressure is elevated (1–6). In fact, prior studies have demonstrated an association of high pulse pressure with microalbuminuria even in subjects without diabetes (7,8). In the current study, we examined the possible association of high pulse pressure and proteinuria (\(\geq 1+\)), i.e., macroalbuminuria, and found that this association was not significant independently of systolic BP in subjects without diabetes. In contrast, systolic BP was significantly associated with proteinuria in these subjects. Although the usefulness of the urine dipstick test for risk stratification of renal and cardiovascular disease has been recognized, this method is a less sensitive measure of albuminuria compared with the measurement of urinary albumin excretion (23–26). Accordingly, we cannot deny the possibility of an association between high pulse pressure and microalbuminuria in subjects without diabetes.

---

**Table 2—OR for the highest quintile of pulse pressure in the association of proteinuria (\(\geq 1+\)) according to the presence of diabetes or prediabetes**

| Model | Adjusted covariates | Diabetes \((n = 27,913)\) | Prediabetes \((n = 100,214)\) | Normal glucose tolerance \((n = 100,651)\) |
|-------|---------------------|--------------------------|-------------------------------|--------------------------------|
| Overall \((n = 228,778)\) | | | | |
| Model 1 | Age + sex + BMI + current smoking + daily drinking + antihypertensive medications + eGFR | 1.72 (1.59–1.87) ‡ | 1.45 (1.35–1.55) ‡ | 1.48 (1.37–1.61) ‡ |
| Model 2 | Model 1 + fasting glucose + triglycerides + HDL + LDL | 1.63 (1.50–1.77) ‡ | 1.41 (1.31–1.50) ‡ | 1.48 (1.36–1.60) ‡ |
| Model 3 | Model 2 + systolic BP | 1.16 (1.05–1.29) ‡ | 0.97 (0.89–1.05) | 1.08 (0.98–1.20) |
| Subjects without antihypertensive medications \((n = 167,110)\) | Diabetes \((n = 16,812)\) | 1.21 (1.03–1.43)* | 1.09 (0.97–1.23) | 1.13 (0.98–1.29) |
| Prediabetes \((n = 71,057)\) | Normal glucose tolerance \((n = 79,241)\) | | | |

OR (95% CI) of proteinuria (\(\geq 1+\)) was calculated for highest quintile of pulse pressure (\(\geq 63\) mmHg, \(n = 40,511)\) vs. lower quintiles of pulse pressure (<63 mmHg) in each model. Statistical significance was defined as \(P < 0.05\). ‡\(P < 0.01\). †\(P < 0.001\)
Pulse pressure and proteinuria

Table 3—OR (95% CI) for proteinuria in diabetes (n = 27,913)

| Model                                                                 | OR (95% CI) | P value |
|----------------------------------------------------------------------|------------|---------|
| Age (+9 years)*                                                      | 0.94 (0.89–1.00) | 0.04    |
| Sex (0, men; 1, women)                                              | 0.55 (0.50–0.60)  | <0.0001 |
| BMI (+3 kg/m²)*                                                     | 1.18 (1.14–1.22)  | <0.0001 |
| Current smoking (0, no; 1, yes)                                     | 1.49 (1.35–1.65)  | <0.0001 |
| Daily drinking (0, no; 1, yes)                                      | 0.90 (0.82–0.99)  | 0.04    |
| Antihypertensive medications (0, no; 1, yes)                        | 0.59 (0.54–0.64)  | <0.0001 |
| eGFR (+16 mL/min/1.73 m²)*                                          | 0.76 (0.73–0.79)  | <0.0001 |
| Fasting glucose (+21 mg/dL)*                                        | 1.20 (1.18–1.22)  | <0.0001 |
| Triglycerides (+78 mg/dL)*                                          | 1.06 (1.03–1.09)  | <0.0001 |
| LDL (+30 mg/dL)*                                                    | 1.07 (1.03–1.11)  | <0.0001 |
| HDL (+16 mg/dL)*                                                    | 1.02 (0.98–1.07)  | 0.39    |
| Systolic BP (+17 mmHg)*                                             | 1.27 (1.20–1.36)  | <0.0001 |
| Pulse pressure (+13 mmHg)*                                          | 1.08 (1.01–1.14)  | 0.02    |

Statistical significance was defined as P < 0.05. *The OR (95% CI) of proteinuria (≥1+) was calculated for a +1 SD increase of each indicated variable as well as dichotomous variables.

In spite of the strict collinearity between systolic BP and pulse pressure, the OR of high pulse pressure to proteinuria was reduced but remained significant even after adjustment for systolic BP in patients with diabetes (Table 2). Table 3 also shows that a +1 SD increase of systolic BP and a +1 SD increase of pulse pressure were associated with proteinuria independently of each other, with the OR of the systolic BP increase on proteinuria being higher than that of the pulse pressure increase. These findings indicate that high systolic BP showed a confirmed association with proteinuria and is an important confounder explaining the association between high pulse pressure and proteinuria, however, even after adjustment for systolic BP, the pulsatile component of BP itself was still significantly associated with proteinuria in patients with diabetes. Intriguingly, even in the patients with diabetes who were within the normal range of systolic BP values, high pulse pressure was associated with proteinuria. Some possible explanations for these findings exist. First, since renal autoregulation is impaired in diabetes (1–3,11–13), it may be possible that when pulse pressure is elevated, more barotrauma-induced glomerular ultrastructural changes leading to albuminuria occur in subjects with diabetes than in those without diabetes (1–5). Second, much as in the previous reports (27,28), higher pulse pressure was observed in diabetics than nondiabetics (Table 1), suggesting the possibility that diabetes accelerates aortic and large arterial stiffness (29). Aortic stiffness itself has a potential etiologic role in the causation and progression of renal dysfunction (30–32), because loss of the damping of ventricular ejection in the stiffened aorta could lead to an increase in the transmission of these pressure changes to the renal microcirculation. In the current study, however, we did not use any measure of vascular stiffness more direct than pulse pressure, such as pulse wave velocity, and thus the potential efficacy of such measures will need to be investigated in the future. Third, overt proteinuria in patients with diabetes, which is observed in long-standing diabetes, together with hypertension and increased arterial stiffness, is a surrogate marker not only for renal structural damages but also generalized vascular damages (3,6,24,25). Therefore, we speculate that patients with diabetes with proteinuria are likely to have systemic vasculopathy, and as a consequence, they have high pulse pressure. Lastly, since the current study is a cross-sectional analysis, we have to pay attention to another possibility that diabetic renal disease indicated by greater proteinuria raises systolic BP as well as pulse pressure rather than the reverse in patients with diabetes.

**Pulse pressure, proteinuria, and prediabetes**

The current study provided the first examination of the association of pulse pressure with proteinuria in prediabetes using a large sample size. Understanding such risk estimates is important, given the increases in the prevalence of prediabetes that have occurred in many populations in conjunction with the increasing prevalence of obesity, particularly in Asian populations (33,34). In the current study, the prevalence of prediabetes was substantially high (44%). Another Japanese study performed in healthy Japanese people (n = 6,636, mean age 50 years) demonstrated that the prevalence of prediabetes was 32% (35). This survey was performed between 1997 and 2003, and since the prevalence of diabetes in Asian populations has increased rapidly in recent years (33,34), the high prevalence of prediabetes in the current study was not entirely unexpected.

Several limitations of our study should be mentioned. First, single-measurement readings of BP, fasting glucose or HbA1c, and proteinuria cannot be considered fully accurate. In particular, some of the dipstick-positive proteinuria could have been transient, and thus could not be taken as definitive evidence of the presence of persisting proteinuria. These factors may introduce a source of variability that could have led to a tendency to underestimate the true association between pulse pressure and proteinuria. Second, we could not separate diabetes into type 1 or type 2 diabetes. However, the incidence of type 1 diabetes is extremely low (approximately two cases/year/100,000 individuals), and Japan has one of the lowest incidence rates of type 1 diabetes in the world (36). Third, we could not assess the diabetes- and atherosclerosis-related information, such as the duration of diabetes and the presence of diabetes complications (e.g., nephropathy), which would be informative and extend the knowledge achieved in the current study. Lastly, we could not assess what kinds of antihypertensive drugs had been prescribed in treated hypertensive subjects. Some antihypertensive drugs (e.g., angiotensin receptor blockers or angiotensin enzyme-converting inhibitors) have more favorable effects on vascular and renal protection (37). Therefore, their use was potentially confounding, although our conclusions remained unchanged when we analyzed our data while excluding the subjects with antihypertensive medications.

In conclusion, among the Japanese general population, high pulse pressure, particularly in individuals with diabetes, was associated with proteinuria, and this information has the potential to supplement other BP indices. To confirm our findings, a prospective study as well as interventions that examine whether or not reduction of pulse pressure can enhance nephroprotective benefits in diabetes will be required.

**Acknowledgments**—This work was supported by Health and Labor Sciences Research grants for “Research on the Positioning of Chronic
References

1. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res 2002;90:1316–1324
2. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200–204
3. Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 2009;32:113–121
4. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375–380
5. Anderson S. Relevance of single nephron studies to human glomerular function. Kidney Int 1994;45:384–389
6. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008;51:714–725
7. Pedrinelli R, Dell'Omo G, Penno G, et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000;35:48–54
8. Cirillo M, Sellato D, Laurenz M, Panarrelli W, Zanchetti A, De Santo NG; The GUBBIO Study Collaborative Research Group. Pulse pressure and isolated systolic hypertension: association with microalbuminuria. Kidney Int 2000;58:1211–1218
9. Farasat SM, Valdes C, Shetty V, et al. Is longitudinal pulse pressure a better predictor of 24-hour urinary albumin excretion than other indices of blood pressure? Hypertension 2010;55:415–421
10. Tsakiris A, Doumas M, Lagatorous D, et al. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology 2006;57:313–320
11. Parving HHH, Kastrup H, Smidt UM, Andersen AR, Feldt-Rasmussen B, Christiansen JS. Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1984;27:547–552
12. Chrisiensen PK, Hansen HF, Parving HHH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997;52:1369–1374
13. Carmine P. The renal vascular response to diabetes. Curr Opin Nephrol Hypertens 2010;19:85–90
14. Knudsen ST, Poulsen PL, Hansen KW, Ebbehøj E, Bæk T, Mogensen CE. Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. Am J Hypertens 2002;15:244–250
15. Palmas W, Moran A, Pickering T, et al. Ambulatory pulse pressure and progression of urinary albumin excretion in older patients with type 2 diabetes mellitus. Hypertension 2006;48:301–308
16. Knudsen ST, Laugesen E, Hansen KW, Bæk T, Mogensen CE, Poulsen PL. Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia 2009;52:698–704
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62–S69
18. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108(Suppl. 3):3B–24B
19. Yano Y, Fujimoto S, Sato Y, et al. Association between prehypertension and chronic kidney disease in the Japanese general population. Kidney Int 2012;81:293–299
20. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Japan Diab Soc 2010;53:450–467
21. Matsuo S, Imai E, Horio M, et al.; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–992
22. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl. 1):S11–S61
23. Iseki K, Ikeymi Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468–1474
24. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17–28
25. de Zeeuw D, Raz I. Albuminuria: a great risk marker, but an underestimated target in diabetes. Diabetes Care 2008;31(Suppl. 2):S190–S193
26. de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 2008;3:616–623
27. Benetos A, Waerbel B, Izzo J, et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 2002;15:1101–1108
28. Schram MT, Kostense PJ, Van Dijk RA, et al. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 2002;20:1743–1751
29. Dart AM, Kingwell BA. Pulse pressure—a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001;37:975–984
30. Ford ML, Tomlinson LA, Chapman TP, Rajkumar C, Holt SG. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010;55:1110–1115
31. Briel M, Collin C, Karras A, et al.; Nephrotic Study Group. Arterial remodeling associates with CKD progression. J Am Soc Nephrol 2011;22:967–974
32. Bouchi R, Babazono T, Mugishima M, et al. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care 2011;34:2570–2575
33. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2128–2140
34. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249–1257
35. Heianza Y, Hara S, Arase Y, et al. HbA1c 5.7–6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011;378:147–155
36. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705–716
37. Paulis L, Unser T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010;7:431–441